10 December 2025

Physiomics plc

("Physiomics" or the "Company")

Physiomics Awarded New Contract by GARDP FOUNDATION

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a new contract in the biometrics department with a new client, GARDP Foundation ("GARDP"). GARDP is a not-for-profit research and development organisation that addresses global public health needs by developing new or improved antibiotic treatments, while endeavouring to ensure sustainable access.

In this project, Physiomics will provide expert consultancy support to GARDP to optimise the design of an efficacy trial in their Serious Bacterial Infections (SBIs) programme. The work for this project is expected to begin January 2026 and is expected to complete within three months.

This project represents an important development in our Biometrics department, being our second major client in this space. We will be providing our client with a strategic partner to support their clinical development plans through optimising design and lean on both the internal expertise at Physiomics, as well as our network of consultants.

Jesse Thissen, Head of Biometrics at Physiomics, commented:

"We're delighted to start our new partnership with GARDP through this project. Utilising our expertise in study design to support clinical development planning aligns perfectly with our mission to help clients make faster, more informed decisions that can help de-risk development and improve outcomes. This project also marks further expansion into new therapeutic areas for Physiomics in Infectious Disease, which has been a target for the Company."

Dr Peter Sargent, CEO of Physiomics, commented:

"This contract award represents a significant milestone for our organisation. Securing our third Biometrics contract since launching the new service line earlier this summer has surpassed our initial projections and underscores the promising contribution this service can make to the Company's growth objectives."

For more information about Physiomics and its services, please visit www.physiomics.co.uk.

Enquiries:

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

Notes to Editor

About Physiomics

Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting-edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.